Powering Innovation that Drives Human Advancement
In silico approaches, powered by physics-based simulation, enable the medical device industry to accelerate innovation, dramatically reduce cost, shorten the regulatory approval process and maximize patient safety.
Join Ansys at The American Medical Device Summit free to inspire, equip, and empower you to innovate your In Silico Medtech practices.
October 1-2, 2024 | Schaumburg, IL
Device failure is not an option regarding well-being and life-saving operations. The medical device industry leverages simulation to develop disruptive innovation and deliver increasingly advanced treatments. Applying engineering simulation throughout the device development cycle and the regulatory approval process is the only cost-effective way to bring new therapies to patients faster while meeting safety standards and satisfying time-to-market deadlines.
Medical device manufacturers have traditionally relied on bench testing, animal testing and clinical trials (i.e., human testing) to establish the safety and efficacy of medical devices.
This is true both internally, when making decisions about various aspects of a device design, and externally when applying for regulatory approval.
These tests can be expensive and time-consuming. Additionally, the ability of animal testing to predict the safety and efficacy of human treatments has come into question.
Knowing that by 2025, 25% of all new pharmaceuticals will use in silico technology andconscious that by 2030, in silico methods will enable 60% more new drugs, the British authorities, industry, and scientific leaders are encouraging the digital transformation of the healthcare industry. Let’s take a few minutes to understand better what computational modeling and simulation mean for the healthcare industry and how they are deployed to provide more time-effective, cost-effective, and environmentally friendly solutions.
We’ll demonstrate the value of combining data with tools to help you narrow down materials options and to ensure the use of approved traceable company data.
Ansys has developed a multidomain, digital system prototyping platform that enables multi-speciality teams with diverse engineering backgrounds to work in unison to achieve a deep understanding of integrated product behavior.
This white paper summarizes the application of this platform to develop a digital system prototype of a wearable insulin pump.
Mark Palmer, Chief Technology Officer - Healthcare, Ansys
